Shanghai Zhimeng Biopharma clinical trials
Shanghai Zhimeng Biopharma is the lead sponsor of 4 current clinical trials in our China and Australia registers. 3 are recruiting patients now. The most common phase is Phase 2. The most-studied condition is Focal Epilepsy.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Shanghai Zhimeng Biopharma
4 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
NCT07238868 · ClinicalTrials.gov ↗ · Focal Epilepsy
|
Phase 2 | Recruiting | 2025-08 | Australia |
|
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
NCT06612775 · ClinicalTrials.gov ↗ · Focal Epilepsy
|
Phase 2 | Recruiting | 2024-08 | Australia |
|
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07082192 · ClinicalTrials.gov ↗ · ALS (Amyotrophic Lateral Sclerosis)
|
Phase 2/3 | Recruiting | 2025-10 | China |
|
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
NCT07095855 · ClinicalTrials.gov ↗ · Chronic Hepatitis B
|
Phase 3 | Not yet open | 2025-08 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Conditions in Shanghai Zhimeng Biopharma trials
3 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in Australia | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Focal Epilepsy
| Sponsor | Trials |
|---|---|
| Biohaven Therapeutics | 3 |
| Rapport Therapeutics | 3 |
| Xenon Pharmaceuticals | 2 |
| Praxis Precision Medicines | 1 |
Sponsors with the most current trials registered for this condition.
Questions about Shanghai Zhimeng Biopharma trials
How many clinical trials does Shanghai Zhimeng Biopharma sponsor?
Shanghai Zhimeng Biopharma is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China and Australia registers, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Shanghai Zhimeng Biopharma trials recruiting?
Yes. 3 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.